M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO PharmaphorumCardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cardio biotech Kardigan binds off $400M upsized IPONext: New biotech cAMPfield emerges with $180M to reshape IBD treatment Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
